- Home
- SVT vs RFL Comparison
SVT vs RFL Comparison
Compare SVT & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SVT
- RFL
- Stock Information
- Founded
- SVT 1959
- RFL 2017
- Country
- SVT United States
- RFL United States
- Employees
- SVT N/A
- RFL 13
- Industry
- SVT Industrial Machinery/Components
- RFL Real Estate
- Sector
- SVT Consumer Discretionary
- RFL Finance
- Exchange
- SVT Nasdaq
- RFL Nasdaq
- Market Cap
- SVT 31.3M
- RFL 41.0M
- IPO Year
- SVT N/A
- RFL N/A
- Fundamental
- Price
- SVT $11.74
- RFL $1.63
- Analyst Decision
- SVT
- RFL
- Analyst Count
- SVT 0
- RFL 0
- Target Price
- SVT N/A
- RFL N/A
- AVG Volume (30 Days)
- SVT 8.9K
- RFL 17.7K
- Earning Date
- SVT 11-07-2024
- RFL 10-28-2024
- Dividend Yield
- SVT N/A
- RFL N/A
- EPS Growth
- SVT N/A
- RFL N/A
- EPS
- SVT 0.17
- RFL N/A
- Revenue
- SVT $46,639,000.00
- RFL $540,000.00
- Revenue This Year
- SVT N/A
- RFL N/A
- Revenue Next Year
- SVT N/A
- RFL N/A
- P/E Ratio
- SVT $39.25
- RFL N/A
- Revenue Growth
- SVT 26.13
- RFL 92.86
- 52 Week Low
- SVT $8.80
- RFL $1.29
- 52 Week High
- SVT $14.10
- RFL $2.30
- Technical
- Relative Strength Index (RSI)
- SVT 46.28
- RFL 62.37
- Support Level
- SVT $11.20
- RFL $1.49
- Resistance Level
- SVT $13.01
- RFL $1.67
- Average True Range (ATR)
- SVT 0.53
- RFL 0.07
- MACD
- SVT -0.12
- RFL 0.02
- Stochastic Oscillator
- SVT 12.15
- RFL 82.08
About SVT Servotronics Inc.
Servotronics Inc is a U.S based company that designs, manufactures, and markets servo valves, including torque motor, hydraulic, and pneumatic valves. The company has single reportable segment which is aerospace Its products are marketed and sold throughout the United States and in select foreign markets. These products are sold to commercial aviation manufacturers, government prime contractors, government subcontractors, and end-users.
About RFL Rafael Holdings Inc. Class B
Rafael Holdings Inc, through its subsidiaries, is a clinical stage, oncology-focused pharmaceutical company committed to the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. The company is a significant investor in two clinical stage oncology companies, Cornerstone Pharmaceuticals, Inc., and LipoMedix Pharmaceuticals Ltd.